全文获取类型
收费全文 | 202512篇 |
免费 | 16438篇 |
国内免费 | 4183篇 |
专业分类
耳鼻咽喉 | 5638篇 |
儿科学 | 3029篇 |
妇产科学 | 3893篇 |
基础医学 | 25849篇 |
口腔科学 | 5436篇 |
临床医学 | 14069篇 |
内科学 | 24414篇 |
皮肤病学 | 2955篇 |
神经病学 | 13497篇 |
特种医学 | 7230篇 |
外国民族医学 | 3篇 |
外科学 | 17060篇 |
综合类 | 26212篇 |
一般理论 | 10篇 |
预防医学 | 16823篇 |
眼科学 | 2839篇 |
药学 | 27048篇 |
96篇 | |
中国医学 | 13910篇 |
肿瘤学 | 13122篇 |
出版年
2023年 | 2628篇 |
2022年 | 3569篇 |
2021年 | 6900篇 |
2020年 | 7862篇 |
2019年 | 9042篇 |
2018年 | 7004篇 |
2017年 | 7768篇 |
2016年 | 7613篇 |
2015年 | 7006篇 |
2014年 | 8585篇 |
2013年 | 13262篇 |
2012年 | 10294篇 |
2011年 | 12255篇 |
2010年 | 8023篇 |
2009年 | 8243篇 |
2008年 | 9653篇 |
2007年 | 10401篇 |
2006年 | 9851篇 |
2005年 | 9119篇 |
2004年 | 7821篇 |
2003年 | 6993篇 |
2002年 | 5514篇 |
2001年 | 5007篇 |
2000年 | 4232篇 |
1999年 | 3493篇 |
1998年 | 2644篇 |
1997年 | 2679篇 |
1996年 | 2432篇 |
1995年 | 2285篇 |
1994年 | 2214篇 |
1993年 | 1862篇 |
1992年 | 1732篇 |
1991年 | 1611篇 |
1990年 | 1393篇 |
1989年 | 1160篇 |
1988年 | 1102篇 |
1987年 | 995篇 |
1986年 | 911篇 |
1985年 | 1335篇 |
1984年 | 1082篇 |
1983年 | 818篇 |
1982年 | 844篇 |
1981年 | 684篇 |
1980年 | 658篇 |
1979年 | 535篇 |
1978年 | 338篇 |
1977年 | 308篇 |
1976年 | 286篇 |
1975年 | 208篇 |
1974年 | 157篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
2.
3.
Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trial
Areej El-Jawahri MD Marlise R. Luskin MD Joseph A. Greer PhD Lara Traeger PhD Mitchell Lavoie BS Dagny Marie Vaughn BS Stephanie Andrews BS Daniel Yang BS Kofi Y. Boateng BS Richard A. Newcomb MD Nneka N. Ufere MD Amir T. Fathi MD Gabriela Hobbs MD Andrew Brunner MD Gregory A. Abel MD Richard M. Stone MD Daniel J. DeAngelo MD PhD Martha Wadleigh MD Jennifer S. Temel MD 《Cancer》2023,129(7):1075-1084
4.
5.
Anna Weiss MD Olga Martínez-Sáez MD PhD Adrienne G. Waks MD Alison Laws MD MPH Monica McGrath BA Paolo Tarantino MD Leah Portnow MD Eric Winer MD María Rey MD Marta Tapia MD Aleix Prat MD PhD Ann H. Partridge MD MPH Sara M. Tolaney MD MPH Juan M. Cejalvo MD PhD Elizabeth A. Mittendorf MD PhD MHCM Tari A. King MD 《Cancer》2023,129(12):1836-1845
6.
7.
8.
9.
Dikshat Gopal Gupta PhD Neelam Varma MD Praveen Sharma MD Mihai I. Truica MD PhD Sarki A. Abdulkadir MD PhD Parmod Singh PhD Man Updesh Singh Sachdeva MD Shano Naseem MD Mohammad Rizwan Siddiqui PhD Parveen Bose MSc Jogeshwar Binota MSc Pankaj Malhotra MD Alka Khadwal MD Amita Trehan Subhash Varma MD 《Cancer》2023,129(21):3390-3404
10.
Naveen Pemmaraju MD Jacqueline S. Garcia MD Andrew Perkins MBBS PhD Jason G. Harb PhD Andrew J. Souers PhD Michael E. Werner PhD Christopher M. Brown PhD Francesco Passamonti MD 《Cancer》2023,129(22):3535-3545
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-XL) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment. 相似文献